Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biologics. 2009;3:159-68. Epub 2009 Jul 13.

Ustekinumab in the therapy of chronic plaque psoriasis.

Author information

  • 1State University of New York, at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USA.

Abstract

Psoriasis is a chronic inflammatory disorder characterized by T cell dysregulation and a chronic inflammatory infiltrate within the epidermis. Several cytokines play an important role in the pathogenesis of psoriasis, including interleukin-12 (IL-12) and IL-23. These cytokines act via induction of pro-inflammatory cytokines which promote chronic inflammation and auto-reactivity. Ustekinumab is a fully human monoclonal antibody against the common p40 subunit of IL-12 and IL-23. Two randomized, double-blind, placebo-controlled trials of ustekinumab have demonstrated significant and prolonged efficacy in the treatment of plaque psoriasis. Adverse events were generally similar across treatment and control groups. Studies are ongoing to assess the long term safety and efficacy profiles of ustekinumab.

KEYWORDS:

plaque; psoriasis; ustekinumab

PMID:
19707405
[PubMed]
PMCID:
PMC2726055
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk